DNA-hsp65 vaccine as therapeutic strategy to treat experimental chromoblastomycosis caused by Fonsecaea pedrosoi

Chromoblastomycosis (CBM) is a chronic subcutaneous mycosis, caused by several dimorphic, pigmented dematiaceous fungi. Patients with the disease are still considered a therapeutic challenge, mainly due to its recalcitrant nature. There is no "gold standard" treatment for this neglected my...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Mycopathologia (1975) 2013-06, Vol.175 (5-6), p.463-475
Hauptverfasser:	Siqueira, Isaque Medeiros, Ribeiro, Alice Melo, Nóbrega, Yanna Karla de Medeiros, Simon, Karina Smidt, Souza, Ana Camila Oliveira, Jerônimo, Márcio Souza, Cavalcante Neto, Florêncio Figueiredo, Silva, Célio Lopes, Felipe, Maria Sueli Soares, Bocca, Anamélia Lorenzetti
Format:	Artikel
Sprache:	eng
Schlagworte:	Amphotericin B Analysis Animals Antifungal Agents - therapeutic use Antiparasitic agents Bacterial Proteins - genetics Bacterial Proteins - immunology Cancer Chaperonin 60 - genetics Chaperonin 60 - immunology Chemotherapy Chromoblastomycosis - microbiology Chromoblastomycosis - pathology Chromoblastomycosis - therapy Colony Count, Microbial Disease Models, Animal DNA Fonsecaea pedrosoi Fungi Health aspects Histocytochemistry Immunologic Factors - administration & dosage Immunologic Factors - genetics Infection Itraconazole Male Mycoses Rats, Wistar Treatment Outcome Tuberculosis vaccines Vaccines, DNA - administration & dosage Vaccines, DNA - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!